Key result
Intracoronary injection of autologous bone marrow mesenchymal stem cells at 4 weeks after acute myocardial infarction significantly increased ejection fraction from 41.3% to 49.7% at 1 month, though the improvement was transient.
Why the study?
Does intracoronary injection of autologous bone marrow mesenchymal stem cells at 2-4 weeks after acute myocardial infarction improve heart function and reduce scar area in patients with myocardial infarction?
Does intracoronary injection of autologous bone marrow mesenchymal stem cells at 2-4 weeks after acute myocardial infarction improve heart function and reduce scar area in patients with myocardial infarction?
Intracoronary injection of autologous bone marrow mesenchymal stem cells at 2-4 weeks post-myocardial infarction appears to be a safe and effective timing for improving cardiac remodeling and function.
It is still unclear whether the timing of intracoronary stem cell therapy affects the therapeutic response in patients with myocardial infarction. The natural course of healing the infarction and the presence of putative homing signals within the damaged myocardium appear to favor cell engraftment during the transendothelial passage in the early days after reperfusion. However, the adverse inflammatory environment, with its high oxidative stress, might be deleterious if cells are administered too early after reperfusion. Here we highlight several aspects of the timing of intracoronary stem cell therapy. Our results showed that transplantation of bone marrow mesenchymal stem cells at 2-4 weeks after myocardial infarction is more favorable for reduction of the scar area, inhibition of left ventricular remodeling, and recovery of heart function. Coronary injection of autologous bone marrow mesenchymal stem cells at 2-4 weeks after acute myocardial infarction is safe and does not increase the incidence of complications.
No takes yet. Share an insight, caveat, or question.
Chen et al. (2014) studied Acute myocardial infarction (n=42). Autologous bone marrow mesenchymal stem cells (BMSCs) vs. Baseline was evaluated on Left ventricular ejection fraction (EF) at 1 month (p=<0.05). Intracoronary injection of autologous bone marrow mesenchymal stem cells at 4 weeks after acute myocardial infarction significantly increased ejection fraction from 41.3% to 49.7% at 1 month, though the improvement was transient.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: